COVID-19 Vaccine Provider Access and Vaccination Coverage Among Children Aged 5–11 Years — United States, November 2021–January 2022

Kim, Christine; Yee, Randy; Bhatkoti, Roma; Carranza, David Bonilla; Henderson, Danielle R.; Kuwabara, Sachiko A.; Trinidad, James P.; Radesky, Sandra; Cohen, Allen Carson; Vogt, Tara M.; Smith, Zachary A.; Duggar, Chris; Chatham‐Stephens, Kevin; Ottis, Christina; Rand, Krista; Lim, Travis; Jackson, Alice F; Richardson, Donald; Jaffe, Aaron; Lubitz, Rachael; Hayes, Ryan J.; Zouela, Aran; Kotulich, Deborah L; Kelleher, Patrick N; Guo, Angela; Pillai, Satish K.; Patel, Anita

doi:10.15585/mmwr.mm7110a4

Cited by 34 publications

(38 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lower uptake for this age group was similarly reported in other studies. 6,15 We found that an additional 35.2% of children had parents who were open to vaccination. These parents could potentially be encouraged to vaccinate their child if vaccine confidence was increased, and access issues were reduced or removed.…”

Section: Discussionmentioning

confidence: 88%

“…This absence of racial/ethnic disparity is encouraging and might be a result of the efforts at outreach to communities to promote and increase access to vaccination. 15,17 Estimates available earlier in the vaccination program showed there might have been some racial/ethnic differences, but they had narrowed by February 2022 when the data for this study were collected. 6,19 It is less encouraging that COVID-19 vaccination coverage was low (< 40%) for all racial/ethnic groups, except for Asian non-Hispanic children.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Factors Associated with Receipt and Parental Intent for COVID-19 Vaccination of Children Ages 5–11 years

Santibanez

Lendon

Singleton

et al. 2022

Preprint

View full text Add to dashboard Cite

Background and ObjectivesCOVID-19 vaccine was first recommended for children ages 5–11 years on November 2, 2021. This report describes COVID-19 vaccination coverage and parental intent to vaccinate their child ages 5–11 years, overall, by sociodemographic characteristics, and by social and behavioral drivers of vaccination, the fourth month after recommendation.MethodsWe analyzed data from 5,438 interviews conducted in February 2022 from the National Immunization Survey-Child COVID Module (NIS-CCM), a national random-digit-dial cellular telephone survey of households with children.Results30.9% of children ages 5–11 were vaccinated with ≥1 dose of COVID-19 vaccine, 35.2% were unvaccinated and the parent reported they probably or definitely would get the child vaccinated or were unsure, and 33.9% were unvaccinated and the parent probably or definitely would not get the child vaccinated. Vaccination coverage and parental intent differed by sociodemographic variables, including income, health insurance status, and rurality. Parental intent to vaccinate children also differed by ethnicity and race. Concern about the child getting COVID-19 and confidence in vaccine importance and safety were positively associated with vaccination receipt and intent to get the child vaccinated.ConclusionsBy the fourth month of the COVID-19 vaccination program for children ages 5–11 years, less than one-third were vaccinated, and coverage was lower for some sociodemographic subgroups. An additional one-third of children had a parent who was open to vaccinating the child. Efforts to address parental concerns regarding vaccine safety and to convey the importance of the vaccine might improve vaccination coverage.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 93%

Factors Associated with Receipt and Parental Intent for COVID-19 Vaccination of Children Ages 5–11 years

Santibanez

Lendon

Singleton

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Although the BNT162b2 COVID-19 vaccine has been deemed safe, immunogenic, and effective in preventing COVID-19 infection ( 16 ), concerns have arisen regarding the risk of myocarditis, especially in adolescents ( 32 – 35 ). This could explain why vaccination rates remain low in children aged 5–11 years old ( 36 ). For example in France, although the BNT162b2 COVID-19 vaccine is available for the children aged 5–11 years old since December 22, 2021, only 5% received at least one dose of as of April 29, 2022.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant

et al. 2022

View full text Add to dashboard Cite

BackgroundIn the midst of successive waves of SARS-CoV-2 variants, the B.1.1.529 (omicron) variant has recently caused a surge in pediatric infections and hospitalizations. This study aimed to describe and compare the symptoms, explorations, treatment and evolution of COVID-19 in hospitalized children during the successive B.1.617.2 (delta) and B.1.1.529 (omicron) waves.MethodsThis observational study was performed in the Pediatric Pulmonology Department of a University Hospital in Paris, France. All hospitalized children aged between 0 and 18 years who tested positive for SARS-CoV-2 using reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal swabs from July 15th to December 15th 2021 (delta wave), and from December 15th 2021 to February 28th 2022 (omicron wave) were included.ResultsIn total, 53 children were included, 14 (26.4%) during the delta wave and 39 (73.6%) during the omicron wave (almost three times as many hospitalizations in half the time during the latter wave). During the omicron wave, hospitalized patients were mostly aged < 5 years (90 vs. 71% of all the children during omicron and delta waves, respectively), and tended to have fewer underlying conditions (56 vs. 79% during omicron and delta waves, respectively, p = 0.20). The omicron variant was also responsible for a different clinical presentation when compared to the delta variant, with significantly higher and often poorly tolerated temperatures (p = 0.03) and increased digestive symptoms (p = 0.01). None of the three patients who were older than 12 years were fully vaccinated.ConclusionThe dramatic increase in the hospitalization of children with COVID-19 and the modification of the clinical presentation between the latest delta and omicron waves require pediatricians to remain vigilant. It should also encourage caregivers to ensure vaccination in children older than 5 years, for whom the BNT162b2 COVID-19 vaccine has been deemed safe, immunogenic, and effective.

show abstract

“…Pharmacies have played an important role in expanding access to COVID-19 vaccines through their availability and extended hours of operation. A previous study found that 46.4% of COVID-19 pediatric vaccine doses were administered in pharmacies (6), indicating that pharmacy vaccine providers are acceptable to many parents. Strategies to improve vaccination coverage among children aged 5-11 years could include encouraging interactions between pharmacy staff members and parents around COVID-19 vaccination.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccine Provider Availability and Vaccination Coverage Among Children Aged 5–11 Years — United States, November 1, 2021–April 25, 2022

DeCuir¹,

Meng²,

Pan³

et al. 2022

MMWR Morb. Mortal. Wkly. Rep.

View full text Add to dashboard Cite

COVID-19 Vaccine Provider Access and Vaccination Coverage Among Children Aged 5–11 Years — United States, November 2021–January 2022

Cited by 34 publications

References 7 publications

Factors Associated with Receipt and Parental Intent for COVID-19 Vaccination of Children Ages 5–11 years

Factors Associated with Receipt and Parental Intent for COVID-19 Vaccination of Children Ages 5–11 years

SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant

COVID-19 Vaccine Provider Availability and Vaccination Coverage Among Children Aged 5–11 Years — United States, November 1, 2021–April 25, 2022

Contact Info

Product

Resources

About